Progenity Inc
NASDAQ:PROG
Progenity Inc
NASDAQ:PROG
Price:
0.69 USD
0.01%
Market Closed
Updated:
Apr 29, 2024
Section:
Relative Value
There is not enough data to reliably calculate the relative value of PROG.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
PROG
Relative Value
Base Case
Not Available
Valuation Multiples
Multiples Across Competitors
PROG Competitors Multiples
Progenity Inc Competitors
Progenity Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Progenity Inc
NASDAQ:PROG
|
127.1m USD | 107.7 | -0.6 | -1.8 | -1.8 | |
| US |
|
Cigna Corp
NYSE:CI
|
103.7B USD | 0.5 | 20.1 | 10.3 | 13.8 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
96.6B EUR | 0.5 | 20 | 10.3 | 13.7 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
86.5B USD | 0.2 | 10.4 | 8.9 | 8.9 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
22.2B EUR | 1.1 | 44.4 | 10.4 | 24.6 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
16.7B USD | 1.4 | 38.6 | 11.8 | 17.7 | |
| DE |
F
|
Fresenius SE & Co KGaA
XETRA:FRE
|
15.4B EUR | 0.7 | -26 | 10 | 22.3 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
14.9B USD | 1.6 | 17.7 | 10.6 | 14.2 | |
| US |
|
DaVita Inc
NYSE:DVA
|
11.9B USD | 1 | 17.1 | 8.4 | 12.3 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.1B EUR | 0.6 | 22.2 | 6.7 | 16 | |
| US |
|
Oak Street Health Inc
NYSE:OSH
|
9.5B USD | 4.4 | -18.6 | -23.3 | -21.5 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
